149 related articles for article (PubMed ID: 36655343)
1. Microsimulation to compare activity-related bleed risks between pharmacokinetic-guided rurioctocog alfa pegol prophylaxis and emicizumab.
Sun SX; Crawford S
Expert Rev Hematol; 2023 Mar; 16(3):205-211. PubMed ID: 36655343
[TBL] [Abstract][Full Text] [Related]
2. Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A.
Sun SX; Frick A; Balasa V; Roberts JC
Expert Rev Hematol; 2022 Oct; 15(10):943-950. PubMed ID: 36000620
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.
Kessler CM; Corrales-Medina FF; Mannucci PM; Jiménez-Yuste V; Tarantino MD
Eur J Haematol; 2023 Nov; 111(5):757-767. PubMed ID: 37587687
[TBL] [Abstract][Full Text] [Related]
5. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study.
Klamroth R; Windyga J; Radulescu V; Collins PW; Stasyshyn O; Ibrahim HM; Engl W; Tangada SD; Savage W; Ewenstein B
Blood; 2021 Apr; 137(13):1818-1827. PubMed ID: 33150384
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
Aledort L; Milligan S; Watt M; Booth J
J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
[TBL] [Abstract][Full Text] [Related]
7. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
Solms A; Shah A; Berntorp E; Tiede A; Iorio A; Linardi C; Ahsman M; Mancuso ME; Zhivkov T; Lissitchkov T
Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials.
Witarto BS; Visuddho V; Witarto AP; Sutanto H; Wiratama BS; Wungu CDK
F1000Res; 2021; 10():1049. PubMed ID: 35136579
[No Abstract] [Full Text] [Related]
9. Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective.
Benson G; Morton T; Thomas H; Lee XY
Clinicoecon Outcomes Res; 2021; 13():39-51. PubMed ID: 33500640
[TBL] [Abstract][Full Text] [Related]
10. Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A:
Escuriola-Ettingshausen C; Klamroth R; Escobar M; Stasyshyn O; Tangada S; Engl W; Honauer I; Lee HY; Chowdary P; Windyga J
Ther Adv Hematol; 2023; 14():20406207231178596. PubMed ID: 37465396
[TBL] [Abstract][Full Text] [Related]
11. Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
Gruppo R; López-Fernández MF; Wynn TT; Engl W; Sharkhawy M; Tangada S
Haemophilia; 2019 Sep; 25(5):773-781. PubMed ID: 31353761
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.
Horling FM; Reipert BM; Allacher P; Engl W; Pan L; Tangada S
Blood Adv; 2024 Jun; 8(11):2726-2739. PubMed ID: 38564770
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in patients with hemophilia A: a secondary analysis of a randomized controlled trial.
Manon-Jensen T; Tangada S; Bager C; Chowdary P; Klamroth R; von Drygalski A; Windyga J; Escobar M; Frederiksen P; Engl W; Ewenstein B; Karsdal M
J Thromb Haemost; 2024 Jan; 22(1):90-100. PubMed ID: 37717853
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
Reyes A; Révil C; Niggli M; Chebon S; Schlagmüller S; Flacke JP; Zortel M; Paz-Priel I; Asikanius E; Hampton R; Mahajan A; Schmidt E; Edwards SC
Curr Med Res Opin; 2019 Dec; 35(12):2079-2087. PubMed ID: 31355677
[No Abstract] [Full Text] [Related]
15. Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study.
Sidonio RF; Thompson AA; Peyvandi F; Stasyshyn O; Yeoh SL; Sosothikul D; Antmen AB; Maggiore C; Engl W; Ewenstein B; Tangada S
Expert Rev Hematol; 2023; 16(10):793-801. PubMed ID: 37646148
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
Rakmanotham A; Moonla C; Sosothikul D
Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
[TBL] [Abstract][Full Text] [Related]
17. A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.
Batt K; Schultz BG; Caicedo J; Hollenbeak CS; Agrawal N; Chatterjee S; Bullano M
Curr Med Res Opin; 2022 Oct; 38(10):1685-1693. PubMed ID: 35880468
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products.
Megías-Vericat JE; Bonanad Boix S; Berrueco Moreno R; Mingot-Castellano ME; Rodríguez López M; Canaro Hirnyk M; Mateo Arranz J; Calvo Villas JM; Haya Guaita S; Mesegué Medà M; López Jaime F; Albo-López C; Palomero-Massanet A; Vilalta Seto N; Leciñena IL; Haro ARC; Poveda Andrés JL
Thromb Res; 2022 Aug; 216():35-42. PubMed ID: 35696967
[No Abstract] [Full Text] [Related]
19. Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States.
Wu Y; Sun SX; Fan T
J Blood Med; 2022; 13():517-524. PubMed ID: 36188439
[TBL] [Abstract][Full Text] [Related]
20. Effects of PK-guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A.
Young G; Callaghan MU; Balasa V; Soni A; Ahuja S; Roberts JC; Simpson ML; Kizilocak H; Frick A; Mokdad AG; Xing S; Caicedo J
Haemophilia; 2023 Sep; 29(5):1234-1242. PubMed ID: 37553998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]